Company intelligence / Profile preview
Enumeral Biomedical
Cambridge, Massachusetts, United Statesenumeral.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Enumeral developed a proprietary immunoprofiling platform to discover monoclonal antibodies targeting immune checkpoint proteins. Its lead programs were pre-clinical PD‑1 antagonists. The company did not advance any candidates into clinical trials before bankruptcy and asset sale.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibody
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Merck Sharp & Dohme Corp.University of Texas MD Anderson Cancer CenterNational Cancer Institute
Beyond the preview
Go deeper on Enumeral Biomedical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Enumeral Biomedical.